Dr. Navid Vahedi Discusses the Most Popular Classic Cars in the World Today

Navid Vahedi

Navid Vahedi

Classic Cars Are an Area of Fascination for Many People, Including Dr. Navid Vahedi, Who Is an Expert on Classic Cars

LOS ANGELES, CA, UNITED STATES, December 2, 2020 /EINPresswire.com/ — There are a lot of people who are looking for the newest cars with the fanciest gadgets; however, there is nothing that is going to beat a classic car. For Dr. Navid Vahedi, classic cars are an area close to his heart. There is nothing like the trip back in time that comes with driving a classic car. Therefore, Dr. Navid Vahedi has turned his hobby into something of a specialty and wants to share everything he knows about classic cars with anyone who will listen. He is here to review the most popular classic cars in the world today.

Dr. Navid Vahedi Discusses the 1969 Dodge Charger
One of the most popular classic cars in the world, according to Dr. Navid Vahedi, is the 1969 Dodge Charger. Dr. Navid Vahedi and many others remember this iconic car because it appeared in the popular TV show The Dukes of Hazzard. While many people remember the iconic vehicle from this show, the popular 1969 Dodge Charger also showed up in the movie Fast and Furious 6. There are a few reasons why people love this charger so much. First, it has a high-powered engine that is sure to deliver everyone the speed and acceleration they are looking for. When this power is combined with the slick look of the car, it is easy to see why so many people love it.

Dr. Navid Vahedi Discusses the 1967 Ford Mustang
Another iconic vehicle that car collectors, such as Dr. Navid Vahedi, love is the Ford Mustang. While there are lots of Ford Mustangs out there, there is nothing like the 1967 Ford Mustang. This year’s model was the first redesign of the iconic original Ford Mustang model. The biggest shift with this model year, according to Dr. Navid Vahedi, was the addition of a big block, V8 engine. This new engine provided added power that drivers noticed instantly. Furthermore, the 1967 Ford Mustang also featured more room on the inside, more cargo space, and a larger body overall. This mustang also featured concave taillights, square rearview mirrors, and even altered side ornamentation!

Navid Vahedi Discusses the 1969 Chevrolet Camaro
Most people, such as Dr. Navid Vahedi, are able to pick out a Camaro instantly on the road; however, the 1969 version of this car is truly special. Even though the mechanical components of this model year Camaro were carried over from the 1968 model, the 1969 model featured a number of new changes. This included new skins, a redesigned grille, and even new paneling. Overall, in the eyes of people such as Navid Vahedi, the sports car simply had a sleeker look that everyone would come to love.

Caroline Hunter
Web Presence, LLC
+17862338220
email us here


Source: EIN Presswire

THE NATIONAL SPACE SOCIETY REMEMBERS BEN BOVA

Ben Bova. Credit: NSS/BenBova.com

Dr. Ben Bova, a visionary author of science fiction, President Emeritus and Governor of the National Space Society, passed on November 29 at the age of 88

Dr. Bova’s writings significantly contributed to NSS’s mission towards the settlement of space and gave us insights into many issues we’ll need to address in the final frontier.”

— Karlton Johnson, Chairman of the NSS Board of Governors

WASHINGTON, D.C., USA, December 2, 2020 /EINPresswire.com/ — “We have lost one of our fellow Governors and President Emeritus of the National Space Society,” said Karlton Johnson, Chairman of the Board of Governors for the NSS. “Dr. Bova’s writings significantly contributed to NSS’s mission towards the settlement of space and gave us insights into many issues we’ll need to address in the final frontier. His insights into the future gave us a glimpse of the possible, and his intellect will be sorely missed.”

Dr. Bova was the author of more than 130 science fiction novels and nonfiction books, and hundreds of articles and essays. His involvement with space technology began with the very origins of the Space Age, working as a technical writer for Project Vanguard, the U.S.’s first satellite program.

Dr. Bova was the winner of many Hugo Awards (considered the premier award in science fiction) and served as the editor of Analog Science Fact & Fiction and OMNI magazine. He was also a president of the Science Fiction and Fantasy Writers of America, a professional author’s group. Dr. Bova received the Lifetime Achievement Award of the Arthur C. Clarke Foundation in 2005, “for fueling mankind’s imagination regarding the wonders of outer space.” His 2006 novel Titan received the John W. Campbell Memorial Award for best novel of the year, and Dr. Bova was elected a Fellow of the American Association for the Advancement of Science (AAAS) in 2001.

Dr. Bova was an active contributor to many NSS endeavors and was critical to the Society’s growth and continued relevance. He was also an enthusiastic educator, teaching at Harvard University and New York’s Hayden Planetarium. Frequently featured on television and radio, he was a gifted communicator regarding space and science. Through his writings and media outreach, Dr. Bova predicted many future technologies, including the use of space solar power to supply Earth’s energy needs, a core value of the NSS.

“Dr. Bova’s guidance and intellectual brilliance will be sorely missed by the NSS, as well as by forward-looking individuals everywhere,” said Dale Skran, the Chair of the NSS’s Executive Committee. “Writers of such a prolific and visionary nature are rare, and the Society was blessed to have such a keen mind involved with its mission.”

The National Space Society was founded in 1987 via a merger of the National Space Institute and the L5 Society. The NSS is the preeminent citizen's voice on space exploration, development, and settlement. To learn more about the NSS and its mission to establish humanity as a spacefaring species, visit us on the web at space.nss.org.

Karlton Johnson
National Space Society
+1 (808) 375-4857
email us here
Visit us on social media:
Facebook
Twitter


Source: EIN Presswire

Global Natural Language Processing (NLP) in Healthcare and Life Sciences Market Industry Forecasts to 2025

A New Market Study, titled “Natural Language Processing (NLP) in Healthcare and Life Sciences Market Upcoming Trends, Growth Drivers and Challenges”

PUNE, MAHARASTRA, INDIA, December 2, 2020 /EINPresswire.com/ — Summary

A New Market Study, titled “Natural Language Processing (NLP) in Healthcare and Life Sciences Market Upcoming Trends, Growth Drivers and Challenges” has been featured on WiseGuyReports.

This report provides in depth study of “Natural Language Processing (NLP) in Healthcare and Life Sciences Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Natural Language Processing (NLP) in Healthcare and Life Sciences Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as profiling, the product outline, the quantity of production, required raw material, and the financial health of the organization.

Request a Free Sample Report @ https://www.wiseguyreports.com/sample-request/5506698-covid-19-impact-on-global-natural-language-processing

This report focuses on the global Natural Language Processing (NLP) in Healthcare and Life Sciences status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Natural Language Processing (NLP) in Healthcare and Life Sciences development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study
3M (Minnesota)
Cerner Corporation (Missouri)
IBM Corporation (New York)
Microsoft Corporation (Washington)
Nuance Communications (Massachusetts)
M*Modal (Tennessee)
Health Fidelity (California)
Dolbey Systems (Ohio)
Linguamatics (Cambridge)
Apixio (San Mateo)

Market segment by Type, the product can be split into
Machine Translation
Information Extraction
Automatic Summarization
Text and Voice Processing
Others

Market segment by Application, split into
Electronic Health Records (EHR)
Computer-Assisted Coding (CAC)
Clinician Document
Others

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Natural Language Processing (NLP) in Healthcare and Life Sciences status, future forecast, growth opportunity, key market and key players.
To present the Natural Language Processing (NLP) in Healthcare and Life Sciences development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Natural Language Processing (NLP) in Healthcare and Life Sciences are as follows:
History Year: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Year 2020 to 2026
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

At Any Query @ https://www.wiseguyreports.com/enquiry/5506698-covid-19-impact-on-global-natural-language-processing

Major Key Points in Table of Content

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Natural Language Processing (NLP) in Healthcare and Life Sciences Revenue
1.4 Market Analysis by Type
1.4.1 Global Natural Language Processing (NLP) in Healthcare and Life Sciences Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Machine Translation
1.4.3 Information Extraction
1.4.4 Automatic Summarization
1.4.5 Text and Voice Processing
1.4.6 Others
1.5 Market by Application
1.5.1 Global Natural Language Processing (NLP) in Healthcare and Life Sciences Market Share by Application: 2020 VS 2026
1.5.2 Electronic Health Records (EHR)
1.5.3 Computer-Assisted Coding (CAC)
1.5.4 Clinician Document
1.5.5 Others
1.6 Coronavirus Disease 2019 (Covid-19): Natural Language Processing (NLP) in Healthcare and Life Sciences Industry Impact
1.6.1 How the Covid-19 is Affecting the Natural Language Processing (NLP) in Healthcare and Life Sciences Industry
1.6.1.1 Natural Language Processing (NLP) in Healthcare and Life Sciences Business Impact Assessment – Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Natural Language Processing (NLP) in Healthcare and Life Sciences Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Natural Language Processing (NLP) in Healthcare and Life Sciences Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

 ….

13 Key Players Profiles
13.1 3M (Minnesota)
13.1.1 3M (Minnesota) Company Details
13.1.2 3M (Minnesota) Business Overview and Its Total Revenue
13.1.3 3M (Minnesota) Natural Language Processing (NLP) in Healthcare and Life Sciences Introduction
13.1.4 3M (Minnesota) Revenue in Natural Language Processing (NLP) in Healthcare and Life Sciences Business (2015-2020))
13.1.5 3M (Minnesota) Recent Development
13.2 Cerner Corporation (Missouri)
13.2.1 Cerner Corporation (Missouri) Company Details
13.2.2 Cerner Corporation (Missouri) Business Overview and Its Total Revenue
13.2.3 Cerner Corporation (Missouri) Natural Language Processing (NLP) in Healthcare and Life Sciences Introduction
13.2.4 Cerner Corporation (Missouri) Revenue in Natural Language Processing (NLP) in Healthcare and Life Sciences Business (2015-2020)
13.2.5 Cerner Corporation (Missouri) Recent Development
13.3 IBM Corporation (New York)
13.3.1 IBM Corporation (New York) Company Details
13.3.2 IBM Corporation (New York) Business Overview and Its Total Revenue
13.3.3 IBM Corporation (New York) Natural Language Processing (NLP) in Healthcare and Life Sciences Introduction
13.3.4 IBM Corporation (New York) Revenue in Natural Language Processing (NLP) in Healthcare and Life Sciences Business (2015-2020)
13.3.5 IBM Corporation (New York) Recent Development
13.4 Microsoft Corporation (Washington)
13.4.1 Microsoft Corporation (Washington) Company Details
13.4.2 Microsoft Corporation (Washington) Business Overview and Its Total Revenue
13.4.3 Microsoft Corporation (Washington) Natural Language Processing (NLP) in Healthcare and Life Sciences Introduction
13.4.4 Microsoft Corporation (Washington) Revenue in Natural Language Processing (NLP) in Healthcare and Life Sciences Business (2015-2020)
13.4.5 Microsoft Corporation (Washington) Recent Development
13.5 Nuance Communications (Massachusetts)
13.5.1 Nuance Communications (Massachusetts) Company Details
13.5.2 Nuance Communications (Massachusetts) Business Overview and Its Total Revenue
13.5.3 Nuance Communications (Massachusetts) Natural Language Processing (NLP) in Healthcare and Life Sciences Introduction
13.5.4 Nuance Communications (Massachusetts) Revenue in Natural Language Processing (NLP) in Healthcare and Life Sciences Business (2015-2020)
13.5.5 Nuance Communications (Massachusetts) Recent Development
13.6 M*Modal (Tennessee)
13.7 Health Fidelity (California)
13.8 Dolbey Systems (Ohio)
13.9 Linguamatics (Cambridge)
13.10 Apixio (San Mateo)

Continued….

Contact Us: sales@wiseguyreports.com

Ph: +1-646-845-9349 (US); Ph: +44 208 133 9349 (UK)

NORAH TRENT
WISE GUY RESEARCH CONSULTANTS PVT LTD
+1 646-845-9349
email us here


Source: EIN Presswire

Space Start-up Is Drastically Cutting the Cost of Rover Missions

MAPP being tested at the Great Sand Dunes.

MAPP in a Thermal Vacuum (TVAC) chamber for qualification testing.

A Colorado based start-up named Lunar Outpost built a lunar rover that will search for resources and carry payloads on the Moon, but not break the bank.

DENVER, CO, USA, December 2, 2020 /EINPresswire.com/ — Space has always been tough. Just surviving outside Earth means that a craft has to withstand the extreme temperature, radiation, vacuum, mechanical stresses, and other rigors of a mission. Building technology that can accomplish this also means that space is expensive. Even if you have the resources for the necessary technology, you still need a ride off the planet. Not exactly a cheap flight you can catch at the airport. All these factors, along with the fact that systems have to be fool-proof because there is no chance of repair, creates missions that only a select few nations can pursue. The MARS 2020 Perseverance Rover that launched this year cost about $2.5 billion; NASA’s VIPER mission is slated to land on the Moon in late 2022 and has a price tag of $250 million for the rover itself [1][2]. But what if you could buy one of these rovers for $100 million? What about $10 million? Less? The barrier to entry for a foot in the door to planetary operations would be drastically reduced, allowing for a far larger pool of customers, as well as a larger pool of suppliers.

That is exactly what a company called Lunar Outpost is doing right now. Founded in 2017, their mission is to create technology that enables an extended human presence in space. They have been working for the past couple years on instrumentation and robotics products, including their Mobile Autonomous Prospecting Platform (MAPP), which will search for valuable resources and carry important payloads on the lunar surface. Their 10kg class version costs in the single digit millions, which is unheard of in the space community. It will also incorporate capabilities not yet exhibited on planetary rovers, like autonomous navigation and operation. Lunar Outpost also has a 300kg class version dubbed HL-MAPP (Heavy Lift-MAPP) that is ready to handle the future of industrial operations in space. And if you don’t need an entire rover, you can purchase one of the payload slots onboard for a fraction of the cost. Now, the MARS 2020 rover is about the size of a small car and has a much longer Martian mission life, so it is in a different category of missions, but VIPER is about the size of HL-MAPP and has a reduced life cycle, so using it as a point of comparison is fairly accurate. One must also note that the cost to launch and land an object on the Moon runs about $1.2 million/kg, so the lighter your payload, the less you pay.

Now why does this matter? Well, this reduction in cost not only lowers the barrier to entry for nation states, but also for other companies and even individuals. This Medium article, “Space is for Everyone”, does a good job of explaining how newer companies like Lunar Outpost, Intuitive Machines, and Masten Space Systems, as well as established primes like Lockheed Martin and SpaceX, are creating a new cis-lunar space economy that will not be completely dependent upon government funding. NASA is very supportive of the commercialization of space and has several programs that are helping to jumpstart this commercialization, such as the Small Business Innovation Research (SBIR) and Commercial Lunar Payload Services (CLPS) programs. The technology and missions funded by these NASA initiatives will provide valuable data back, as well as support NASA’s upcoming manned Artemis landings.

Ultimately, the utilization of resources found on the Moon will create a sustainable and long-term presence for humans in space. The oxygen and hydrogen will be used to fuel lunar operations, deep space missions, as well as satellites orbiting the Earth. Lunar Outpost’s fleet of MAPP rovers will be key to finding and classifying these resources. In this new era of space exploration, the ingenuity, determination, and effort of entities of all sizes will be on display. And soon when we look up at the Moon, people will be looking back. Along with a few rovers, too.

1. https://www.space.com/mars-2020-rover-cost-overruns-impact-other-missions.html#:~:text=The%20initial%20proposed%20cost%20for%20the%20rover%2C%20when,that%20the%20cost%20had%20soared%20to%20%242.46%20billion.
2. https://spacenews.com/astrobotic-wins-nasa-contract-to-deliver-viper-lunar-rover/#:~:text=At%20that%20time%2C%20NASA%20expected%20to%20launch%20VIPER%2C,estimated%20cost%20of%20%24250%20million%2C%20in%20late%202022.

Julian Cyrus
Lunar Outpost
email us here


Source: EIN Presswire

rfxcel Responds to Unprecedented Cold Chain Requirements and Logistics Challenges as COVID-19 Vaccine Distribution Nears

rfxcel traceability system

Safety through traceability

rfxcel, the global leader in digital supply chain traceability solutions, responds to cold chain and logistics challenges as COVID-19 vaccine distribution nears

RENO, NEVADA, UNITED STATES, December 2, 2020 /EINPresswire.com/ — rfxcel, the global leader in digital supply chain traceability solutions, continues to address cold chain and logistical challenges it anticipates will arise from the first widespread distribution of COVID-19 vaccines. The company has been preparing for a “vaccine surge” since the pandemic began to ensure it can respond to customer and industry needs when distribution begins to exert pressure on supply chains.

“The pandemic has revealed shortcomings in every supply chain, and we’ve seen increased competition for resources,” said rfxcel CEO and Co-Founder Glenn Abood. “We’ve worked with our global customers in pharma/life sciences, food and beverage, consumer goods, and government to keep their operations responsive and nimble. Now, we’re prepared to address additional stresses distribution of COVID-19 vaccines could create as the call for ‘all hands on deck’ commences and already scarce resources are redirected for the effort.”

rfxcel has provided traceability solutions since 2003. Its rfxcel Traceability System comprises discrete solutions that work in concert to harmonize, optimize, automate, and monitor supply chain operations, including serialization, compliance, environmental monitoring, raw materials traceability, and data analytics.

The company’s Integrated Monitoring (rIM) solution uses Internet of Things (IoT) technology to monitor the environmental condition of products in real time as they move through supply chains on land, sea, and air. rIM communicates with small IoT-enabled devices embedded with products and sends updates and alerts about more than a dozen environmental conditions, such as temperature, location, humidity, light, and shock. It can alert users about route diversions and ensure logistics providers remain in compliance with delivery agreements.

rfxcel has also developed Accurate Immunization Management (AIM), an automated, cloud-based solution that tracks the dispensing of vaccines. It seamlessly integrates with critical healthcare applications such as Electronic Health Records (EHRs) and Immunization Information Systems (IIS). It empowers healthcare practitioners to view patients’ immunization records in real time, manage accurate administering, monitor inventory, and safely dispense the right vaccines to the right patient at the right time. Because it is automated, users can be up and running with virtually no training, ensuring quick implementation in mission-critical locations.

“We want to provide foolproof traceability,” Abood said. “Today, it’s more important than ever to be able to question, examine, and control every part of the supply chain, which is what our rfxcel Traceability System platform provides with solutions such as rIM and AIM.”

For more information about rfxcel’s Traceability System, rIM, AIM, and other solutions, contact Herb Wong, vice president of marketing and strategic initiatives.

Herb Wong
rfxcel Corporation
+1 925-824-0300
email us here

rfxcel: A Leader in Patient Safety through Traceability


Source: EIN Presswire

CDI Energy Products Singapore Manufacturing Receives API Q1 Certification

Singapore Manufacturing Facility Achieves API Q1 Certification

Singapore Manufacturing Facility Achieves API Q1 Certification

CDI Energy Products announced today that after a lengthy multistage audit, its Singapore manufacturing facility has successfully received API Q1 Certification.

API Q1 advances our Operational Excellence goals and reaffirms that we are on the right path for our customers, our global community, and our environment.”

— Richard Stone, General Manager

HOUSTON, TX, UNITED STATES, December 2, 2020 /EINPresswire.com/ — CDI Energy Products, a global leader in high-performance polymer products, announced today that after a lengthy multistage audit, its Singapore manufacturing facility has successfully received API Q1 Certification. CDI’s Singapore location is respected in the Middle East, Asia Pacific, and China markets for its superior turnkey services for standard and customized polymer products. A top-rated Quality Management System is a key component in CDI’s global deliverability.

“Continually improving ourselves is part of our culture and API Q1 is the next step in our journey,” says Richard Stone, General Manager. “We are driven to meet and exceed the demands of our customers, and to maintain safety and quality in every stage of the production process. API Q1 advances our Operational Excellence goals and reaffirms that we are on the right path for our customers, our global community, and our environment.”

API Spec Q1 titled "Specification for Quality Management System Requirements for Manufacturing Organizations for the Petroleum and Natural Gas Industry" is a company level certification based on the standards developed and published by the American Petroleum Institute (API). This certification is intended for companies who manufacture equipment or components of equipment used in oil and natural gas production. Certifications are issued exclusively by API. Companies must submit their quality manual for approval and host an on-site audit conducted by an API official. Companies must have a quality system in place meeting the risk-mitigation requirements outlined in the industry standards. Annual audits are conducted to ensure consistent adherence to industry standards.

In July 2020, CDI’s Houston manufacturing facility successfully completed the API Spec Q1 Recertification process. With the Singapore location achieving the API Q1 Certification, the facility’s recognition for high-level processes and operations reflects its reliable in-region manufacturing, trusted customer partnership, and enhanced deliverability. Across its global footprint, CDI is committed to operational safety and quality for every stage in the prototype-to-production process.

“We are constantly researching and developing new methods, materials, and components to support the ever-evolving needs of the robust energy markets. We are expanding our midstream and downstream business specifically in the Asia Pacific region with a focus on high-performance components and custom polymer materials to meet our customers’ critical applications. API Q1 reinforces that our level of quality is something on which customers can rely,” says Stone.

By early 2021, CDI’s Singapore location will add new manufacturing equipment to enhance its milling capabilities. Furthering its dedication to continuous improvement, new equipment, IoT initiatives, and other smart manufacturing enhancements will enhance CDI’s manufacturing capabilities and global customer deliverability.

Kari Schoeffler
CDI Energy Products
+1 832-785-9304
email us here
Visit us on social media:
LinkedIn
Facebook
Twitter

CDI Critical Components for Critical Applications


Source: EIN Presswire

AVM Biotechnology President Selected to Speak at ESWI Conference in Novel and Outstanding Discoveries Track

Dr. Theresa Deisher

AVM Biotechnology

Dr. Theresa Deisher has been invited to provide an oral presentation in the Novel & Outstanding Discoveries Track at the 2020 ESWI Virtual Conference

“I’m honored to be able to present our data, which speaks to the importance of the work being done at the company as well as the broad and significant potential of AVM0703”.”

— Dr. Theresa Deisher

SEATTLE, WA, USA, December 2, 2020 /EINPresswire.com/ — AVM Biotechnology, a company developing a proprietary and innovative form of dexamethasone, today announced that CEO/CSO, Dr. Theresa Deisher has been selected to present during the Novel and Outstanding Discoveries Track at the European Scientific Working Group on Influenza (ESWI). The ESWI 2020 Virtual Conference will run from December 6-9, connecting worldwide experts on Influenza, RSV, and COVID-19. Registration is still open and can be accessed at https://influenzaconference.org/register/register-now.

Dr. Deisher’s presentation entitled “Acute Suprapharmacologic Dexamethasone Mobilizes Natural Killer T and Cytotoxic T cells for Influenza A/B-induced or COVID-19-induced Acute Respiratory Distress Syndrome (ARDS)” will be streamed live during the conference on December 9th.

“I’m honored to be able to present our data, which speaks to the importance of the work being done at the company as well as the broad and significant potential of AVM0703”, Dr. Deisher said.

Acute suprapharmacologic dexamethasone sodium phosphate as AVM0703 mobilizes very active Natural Killer T-cells (NKT) and cytotoxic T-cells. Low doses of generic dexamethasone are currently the standard of care in COVID-19 disease and mitigate cytokine release that can trigger ARDS. The high dose of dexamethasone provided by AVM0703 is expected to provide an added benefit to these patients because NKT cells are programmed to eliminate abnormal cells, whether cancer or virus-infected, or autoreactive cells. Rapid elimination of infected monocytes in COVID-19 patients could reduce ICU stays and decrease long-term lung damage as well as provide long term immunity. Since this treatment is microbial strain independent, it could provide an immediate therapy for future pandemics. AVM Biotechnology is currently enrolling patients with Relapsed Refractory Non-Hodgkin’s Lymphoma at several US sites, and has received FDA approval to treat moderate to severe ARDS due to COVID-19 or Influenza, enrolling Q1 2021.

AVM0703 is a patent-pending, innovative formulation of dexamethasone. This proprietary formulation does not contain excipients such as benzyl alcohol and parabens used in generic formulations which preclude the safe use of generic versions at the acute doses required to mobilize the AVM0703 novel immune cells. AVM0703 is expected to have therapeutic effects in a variety of blood cancers, solid tumors, Type 1 Diabetes, and infectious diseases. Despite the availability of vaccines and anti-virals, influenza continues to lead to ARDS in a substantial number of patients each year. COVID-19 induced ARDS is also likely to continue to be problematic, even after vaccines are available.

AVM Biotechnology is led by Dr. Theresa Deisher, a biotech veteran with a productive history including 47 patents and four discoveries in clinical trials. AVM’s COO, Janet R. Rea, has a proven track record working with federal regulators and successfully bringing drugs to market. The Executive Board is comprised of world leaders in the areas of respiratory illness, regulatory affairs, and vaccine development, and AVM is guided by a Global Advisory Board that includes well-respected leaders in the areas of cancer and immunology. The company has received two federal SBIR grants and holds eight worldwide patent families protecting its intellectual property. AVM is committed to transforming the future of immunotherapy while reducing the potential for undesirable treatment side effects.

Contact Jena Dalpez Director of Communications and Public Relations jdalpez@avmbiotech.com

This contains certain statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not relate strictly to historical or current facts and they may be accompanied by words such as “could,” “would,” “may,” “potentially,” “suggest,” “believes,” “expects,” “should,” and similar words or expressions. These forward-looking statements reflect our current views as of the date this is published, and are subject to risks, uncertainties, assumptions, changes in circumstances, and other factors; drug development and commercialization are highly risky and early clinical results in animals or humans may not reflect the full results from later stage or larger scale clinical trials. These forward-looking statements are subject to risks and uncertainties that could cause our actual results, performance, and expectations to differ materially from those expressed or implied by these statements, including statements about: future and ongoing drug development and timing; the applications of drugs to specific diseases; the potential for ongoing preclinical or clinical trial results; FDA or other regulatory findings and approvals; potential market opportunities; and the occurrence of future events or circumstances. There are risks and uncertainties involving and not limited to our ability to progress in our research and development efforts, complete clinical testing, achieve our expected results, commercialize our products, avoid infringement of patients, trademarks and other proprietary rights of third parties, protect products from competition, navigate the political environment, maintain sufficient capital and funding, avoid problems with our manufacturing processes, maintain our operations, and obtain regulatory approval to sell and market the drugs in the United States and elsewhere. The reader should not place any undue reliance on such forward-looking statements. We have no obligation to release publicly the results of any revisions to any of our forward-looking statements to reflect events or circumstances after the date these statements are made or to reflect the occurrence of unanticipated events, except as may be required by law.

Jena Dalpez
AVM Biotechnology
+1 206-906-9922
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

An explanation of AVM0703


Source: EIN Presswire

Seven Stars RTC Introduces Brainspotting to Help Teens on the Spectrum Heal from Trauma

Seven Stars RTC

Seven Stars RTC

SYRACUSE, UTAH, UNITED STATES, December 2, 2020 /EINPresswire.com/ — Seven Stars RTC, one of the nation’s premier residential treatment centers for teens with autism and other neurodevelopmental disorders, has introduced brainspotting to their clinical programming. Even though brainspotting is a fairly new treatment modality for trauma, initial studies have indicated similar outcomes when compared to EMDR therapy. Seven Stars therapists report that it has been a great addition to their therapeutic services, especially for students who benefit from a more somatic approach.

What is Brainspotting?

Brainspotting is a treatment that evolved out of EMDR therapy. It uses points in a client’s visual field as a tool for healing. “This treatment modality can provide relatively rapid change for trauma, depression, and anxiety,” says Dr. Gordon Day, Seven Stars RTC’s Founder and Executive Clinical Director. It is thought that Brainspotting helps clients access the deeper parts of their brain where traumatic memories are held. It is a creative way to engage teens with Autism Spectrum Disorder who often have a hard time with other more traditional ways of reprocessing trauma.

“What is interesting about brainspotting is that students can still work through a traumatic event even if they don’t have the language to describe it, which is common with teenagers on the Autism Spectrum,” says Rachelle Steed, LCSW, Primary Therapist at Seven Stars. “This is important because often the kids we work with struggle to find words to express how they are feeling. Structured techniques, like brainspotting, help them form new neural networks, which then helps them find prosocial ways to resolve the trauma or roadblocks they are facing.” By healing past traumatic events, brainspotting also helps students overcome the depression and anxiety associated with these events.

How is Brainspotting Practiced at Seven Stars RTC?

During a brainspotting session, Seven Stars RTC’s primary therapists help students access a “brainspot” (a point in visual space that a client has a strong reaction to) by either helping students identify where they feel memories in their body or by using reflexes depending on where they are looking. “When a brainspot is stimulated, the deep brain reflexively signals the therapist that the source of the trauma has been accessed,” says Rachelle Steed. “From there, we teach clients how to become more aware of their bodies and teach them grounding tools that are helpful to their healing.”

Brainspotting is particularly useful with teenagers, whose brains are naturally more neuroplastic and open to changes. Generally, teenagers on the Autism Spectrum struggle with rigid thinking, communication, and feeling “outside” their bodies. Seven Stars RTC has found brainspotting to be a useful tool to help teenagers with neurodiverse minds gain greater cognitive flexibility and heal from trauma. “We are very happy with the progress our students have made thanks to this new treatment modality and are excited to see upcoming research on the benefits of brainspotting for neurodiverse students,” says Dr. Day.

Dr. Gordon Day
Seven Stars RTC
+1 (844) 601-1167
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Fruit Concentrate Market 2020 Size, Trends, Industry Analysis, Leading Players & Future Forecast by 2025

A new market study, titled “Fruit Concentrate Market Research Report- Forecast to 2023”, has been featured on WiseGuyReports.

PUNE, MAHARASTRA, INDIA, December 2, 2020 /EINPresswire.com/ — Fruit Concentrate Market

The Fruit Concentrate market report gives an integrated insight into the industry and the core components that influence its performance at the global level. A brief explanation of the chief market offering has been highlighted along with its use in the end-user industry. The chief elements that exist in the market setting and influence the business landscape have been identified and critically examined. On the basis of the detailed assessment, the growth potential of the Fruit Concentrate market at the global level for the forecasted period of 2020 to 2025 has been determined.

The major players in global fruit concentrates market include:

Agrana Beteiligungs AG (Austria)
• China Haisheng Fresh Fruit Juice Co., Ltd (Hong Kong)
• Döhler Group (Germany)
• Kerr Concentrates, Inc. (US)
• Kerry Group PLC (Ireland)
• Royal Cosun (Netherlands)
• SunOpta, Inc. (Canada)
• Rudolf Wild Gmbh & Co. KG (Germany)

Request Free Sample Report at https://www.wiseguyreports.com/sample-request/3944421-fruit-concentrate-market-research-report-forecast-to-2023

Insight into the Fruit Concentrate market

A broad range of factors exist in the industry and influence the business environment. In the Fruit Concentrate market report, the micro and macro factors that exist in the market have been identified and explained. Some of the key factors that have been assessed are the adoption of latest technology the market participants, the fluctuation in the level of supply and demand in the market and the expansion of the global population. The initiatives that have been taken by the government influencing the market have also been examined. Similarly, special attention has been given to the intense market competition as it affects the market performance.

Evaluation of market segments

The Fruit Concentrate market has been segmented on the basis of a broad range of aspects such as the end-use application, type, and geographical regions. A detailed segmentation analysis has been performed to identify the underlying factors that influence the market performance. Some of the chief geographical regions that have been identified and examined in the market report include Latin America, Europe, North America, the Asia Pacific and the Middle East and Africa. The performance of the business participants in each of the geographical regions shapes the ultimate performance of the market at the global level.

Research methodology

An inclusive research of the Fruit Concentrate market has been carried out by the qualified market research team. Strategic approaches and tools have been used for conducting the research and analysis of the market. SWOT analysis has been performed which has highlighted the strengths, weaknesses, threats and opportunities that mold the quality of the market environment. The competitive intensity that is prevalent in the market has been examined by using Porter’s Five Force model.

Players in the market

The key market players that function in the Fruit Concentrate market have been identified. An exhaustive examination of these market players has been performed, including the strategic approaches that are adopted by them to gain an edge over their competitors and reach the vast market audience.

View Detailed Report at https://www.wiseguyreports.com/reports/3944421-fruit-concentrate-market-research-report-forecast-to-2023

About Us:
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

NORAH TRENT
WISE GUY RESEARCH CONSULTANTS PVT LTD
+1 646-845-9349
email us here


Source: EIN Presswire

Survivors of Lethal Drug & Shock Deep Sleep Therapy Vindicated After 30 Years

Survivors of Lethal Drug & Shock Deep Sleep Therapy Vindicated After 30 Years

An Australian judge’s condemnation of a dangerous psychiatric treatment linked to 48 deaths and once used in U.S. mind-control experiments, ignites new calls for a global ban on electroshock treatment.

Australian judge’s condemnation of a dangerous psychiatric treatment linked to 48 deaths and used in mind-control experiments, ignites new calls for ban on ECT

LOS ANGELES, CALIFORNIA, UNITED STATES, December 1, 2020 /EINPresswire.com/ — Citizens Commission on Human Rights International, a mental health industry watchdog, said a recent finding by an Australian federal judge has vindicated hundreds of patients subjected to potentially lethal Deep Sleep Treatment (DST) involving heavy psychotropic drugs and electroshock. Jan Eastgate, the international president of CCHR, said the group helped get the practice banned in New South Wales in 1983 following 48 deaths. It also exposed its use in U.S. Central Intelligence Agency (CIA)-funded brutal experiments during the 50s and 60s, where patients were electroshocked while in a drug-induced coma.[1] But a judgement on November 25, 2020 has reignited calls for electroshock treatment (ECT) used in DST to also be banned.

The Australian findings were in relation to two former DST doctors who questioned the publication of a 2016 book, the author of which had re-hashed the findings of an NSW Royal Commission into DST in 1988-1990, and other reports, including coroner inquests. CCHR and a nurse, Rosa Nicholson, had played a pivotal role in obtaining the re-opening of coroner inquests that linked DST to the deaths, and other actions leading to the $15 million government inquiry that condemned DST. Two DST doctors waited nearly 30 years to challenge the Commission findings that relied upon testimony from patients, CCHR, nurses, and international experts that condemned DST. The experts also were critical of the way in which ECT was practiced at the now-closed for-profit Chelmsford psychiatric hospital. (Read article on the case[2])

In a multi-million-dollar challenge, this year’s findings were the opposite of what the doctors, one a former deregistered psychiatrist, had anticipated.[3] Judge Jayne Jagot of the Australian Federal Court NSW Registry reinforced the Royal Commission findings, stating the Commission’s report “exposed atrocities and horrors at Chelmsford and the applicants’ roles in perpetuating those atrocities and horrors on patients who, on any reasonable view, were the victims” of “gross negligence, unethical conduct and medical malpractice.”

Further, “In my view, the very nature of DST was dehumanizing and traumatizing. Patients and their families were not informed about what was proposed. Patients were rendered effectively comatose for no good reason, for lengthy periods, making them defenseless, helpless, and incontinent. While sedated they were subjected to ECT without anesthetic, oxygen or muscle relaxants.”

The case reflects problems that still exist with electroshock today, including in the U.S. As used in DST, Judge Jagot said: “Many patients were not told they would be given ECT, and if they had known, would never had allowed it.” Eastgate, whose CCHR headquarters are in Los Angeles, said: “In the U.S. today, statistics on the number of patients forced to undergo ECT without consent or based on misleading, if not fraudulent, information is not maintained. Consumer fraud is notorious, because often patients are not informed ECT causes brain damage.”

Judge Jagot also stated: “ECT was open to abuse and was routinely abused” at Chelmsford hospital. “This reinforces my conclusion that it is likely that no patient gave informed consent to DST because no patient would have knowingly consented to a procedure with such a serious risk of harm and death had they been informed (as they should have been) about available alternatives and that DST was an experimental and unproven procedure.”

Eastgate and the former Chelmsford Hospital whistle-blower nurse, the late Rosa Nicholson, worked together for many years exposing DST and ECT in Australia. Judge Jagot’s judgement reinforced the vindication Nicholson obtained in the Royal Commission. The nurse had photocopied records as evidence against DST, which CCHR turned over to the NSW Attorney General to act and which helped CCHR to get four coroner’s inquests re-opened.[4] Eastgate and Nicholson met following a DST psychiatrist who was publicly exposed for his sexual affair with a patient he’d electroshocked and her subsequent suicide. The psychiatrist, himself, was put under DST after this and years later committed suicide.

When the DST case arose again this year after so many years, Eastgate, wrote a tribute to the nurse to reinforce the facts about her work.

As Judge Jagot quoted, “Rosa Nicholson became the central figure in exposing the truth about the dozens of deaths caused by medical malpractice inside Chelmsford Hospital.” Further, her contribution “to the exposure of the iniquitous goings-on at Chelmsford was a worthwhile endeavour that has increased, not reduced, the total sum of human knowledge.”

In a united effort, patient survivors of DST, especially the late former actor, Barry Hart, their families, nurses, several journalists, legislators and CCHR, provided a legacy of patient rights, which CCHR says are currently being undermined in Australia that has seen a nearly 50% increase in the use of ECT since 2010. In the U.S., over 100,000 Americans every year are subjected to ECT, some aged 0-5, according to State information. The over $3 billion a year industry prompted CCHR’s latest documentary, Therapy or Torture? The Truth About Electroshock, which includes the story of DST.

The delivery of DST in NSW is a criminal offense under the NSW Mental Health Act, while in Western Australia, ECT is banned and carries a jail sentence and/or financial fine if administered to minors. In the U.S., CCHR and ECT survivors were also instrumental in obtaining a ban on ECT use on minors in four states. CCHR wants to see such a ban extend to all age groups globally. An online petition also supports a ban on ECT.

CCHR International also encourages patients damaged by ECT or their families to report this to the group using its online abuse report form here: https://www.cchrint-programs.org/acms/case/create

CCHR is a mental health watchdog responsible for more than 180 laws that protect patients from damaging psychiatric practices. DONATE to support its work here: https://www.cchrint.org/cchrint-donate/

[1] “1950s–1960s: Dr. Ewen Cameron Destroyed Minds at Allan Memorial Hospital in Montreal,” AARP, 18 Jan. 2015, https://ahrp.org/1950s-1960s-dr-ewen-cameron-destroyed-minds-at-allan-memorial-hospital-in-montreal/; “Deep Sleep Treatment Death Nightmare Awakes 30 Years Later to Condemn Current Psychiatric Practices,” TruthAboutECT.org, updated 27 Nov. 2020, https://truthaboutect.org/deep-sleep-treatment-death-nightmare-awakes-30-years-later/

[2] “Deep Sleep Treatment Death Nightmare Awakes 30 Years Later to Condemn Current Psychiatric Practices,” TruthaboutECT.org, updated 27 Nov. 2020, https://truthaboutect.org/deep-sleep-treatment-death-nightmare-awakes-30-years-later/

[3] “‘Deep sleep therapy’ doctors lose multi-million-dollar fight to clear their names: Dr John Gill, a former GP and deregistered psychiatrist John Herron used defamation laws to try and ‘rewrite history,’” Australian Doctor, 26 Nov. 2020.

[4] John Adams inquest (26 Jan. 1978 and Jan. 1980); Sharon Hamilton (March/April 1979); Miriam Podio (1982); Audrey Francis (1986)

Amber Rauscher
Citizens Commission on Human Rights
+1 323-467-4242
email us here
Visit us on social media:
Facebook
Twitter


Source: EIN Presswire